Browsing by Author "Oguzulgen I.K."

Now showing 1 - 6 of 6
  • No Thumbnail Available
    Item
    The predictors of COVID-19 mortality in a nationwide cohort of Turkish patients
    (W.B. Saunders Ltd, 2021) Kokturk N.; Babayigit C.; Kul S.; Duru Cetinkaya P.; Atis Nayci S.; Argun Baris S.; Karcioglu O.; Aysert P.; Irmak I.; Akbas Yuksel A.; Sekibag Y.; Baydar Toprak O.; Azak E.; Mulamahmutoglu S.; Cuhadaroglu C.; Demirel A.; Kerget B.; Baran Ketencioglu B.; Ozger H.S.; Ozkan G.; Ture Z.; Ergan B.; Avkan Oguz V.; Kilinc O.; Ercelik M.; Ulukavak Ciftci T.; Alici O.; Nurlu Temel E.; Ataoglu O.; Aydin A.; Cetiner Bahcetepe D.; Gullu Y.T.; Fakili F.; Deveci F.; Kose N.; Tor M.M.; Gunluoglu G.; Altin S.; Turgut T.; Tuna T.; Ozturk O.; Dikensoy O.; Yildiz Gulhan P.; Basyigit I.; Boyaci H.; Oguzulgen I.K.; Borekci S.; Gemicioglu B.; Bayraktar F.; Elbek O.; Hanta I.; Kuzu Okur H.; Sagcan G.; Uzun O.; Akgun M.; Altinisik G.; Dursun B.; Cakir Edis E.; Gulhan E.; Oner Eyuboglu F.; Gultekin O.; Havlucu Y.; Ozkan M.; Sakar Coskun A.; Sayiner A.; Kalyoncu A.F.; Itil O.; Bayram H.
    The COVID-19-related death rate varies between countries and is affected by various risk factors. This multicenter registry study was designed to evaluate the mortality rate and the related risk factors in Turkey. We retrospectively evaluated 1500 adults with COVID-19 from 26 centers who were hospitalized between March 11 and July 31, 2020. In the study group, 1041 and 459 cases were diagnosed as definite and highly probable cases, respectively. There were 993 PCR-positive cases (66.2%). Among all cases, 1144 (76.3%) were diagnosed with non-severe pneumonia, whereas 212 (14.1%) had severe pneumonia. Death occurred in 67 patients, corresponding to a mortality rate of 4.5% (95% CI:3.5–5.6). The univariate analysis demonstrated that various factors, including male sex, age ≥65 years and the presence of dyspnea or confusion, malignity, chronic obstructive lung disease, interstitial lung disease, immunosuppressive conditions, severe pneumonia, multiorgan dysfunction, and sepsis, were positively associated with mortality. Favipiravir, hydroxychloroquine and azithromycin were not associated with survival. Following multivariate analysis, male sex, severe pneumonia, multiorgan dysfunction, malignancy, sepsis and interstitial lung diseases were found to be independent risk factors for mortality. Among the biomarkers, procalcitonin levels on the 3rd-5th days of admission showed the strongest associations with mortality (OR: 6.18; 1.6–23.93). This study demonstrated that the mortality rate in hospitalized patients in the early phase of the COVID-19 pandemic was a serious threat and that those patients with male sex, severe pneumonia, multiorgan dysfunction, malignancy, sepsis and interstitial lung diseases were at increased risk of mortality; therefore, such patients should be closely monitored. © 2021 Elsevier Ltd
  • No Thumbnail Available
    Item
    The association of antiviral drugs with COVID-19 morbidity: The retrospective analysis of a nationwide COVID-19 cohort
    (Frontiers Media S.A., 2022) Babayigit C.; Kokturk N.; Kul S.; Cetinkaya P.D.; Atis Nayci S.; Argun Baris S.; Karcioglu O.; Aysert P.; Irmak I.; Akbas Yuksel A.; Sekibag Y.; Baydar Toprak O.; Azak E.; Mulamahmutoglu S.; Cuhadaroglu C.; Demirel A.; Kerget B.; Baran Ketencioglu B.; Ozger H.S.; Ozkan G.; Ture Z.; Ergan B.; Avkan Oguz V.; Kilinc O.; Ercelik M.; Ulukavak Ciftci T.; Alici O.; Nurlu Temel E.; Ataoglu O.; Aydin A.; Cetiner Bahcetepe D.; Gullu Y.T.; Fakili F.; Deveci F.; Kose N.; Tor M.M.; Gunluoglu G.; Altin S.; Turgut T.; Tuna T.; Ozturk O.; Dikensoy O.; Yildiz Gulhan P.; Basyigit I.; Boyaci H.; Oguzulgen I.K.; Borekci S.; Gemicioglu B.; Bayraktar F.; Elbek O.; Hanta I.; Kuzu Okur H.; Sagcan G.; Uzun O.; Akgun M.; Altinisik G.; Dursun B.; Cakir Edis E.; Gulhan E.; Oner Eyuboglu F.; Gultekin O.; Havlucu Y.; Ozkan M.; Sakar Coskun A.; Sayiner A.; Kalyoncu A.F.; Itil O.; Bayram H.
    Background and objectives: Although several repurposed antiviral drugs have been used for the treatment of COVID-19, only a few such as remdesivir and molnupiravir have shown promising effects. The objectives of our study were to investigate the association of repurposed antiviral drugs with COVID-19 morbidity. Methods: Patients admitted to 26 different hospitals located in 16 different provinces between March 11–July 18, 2020, were enrolled. Case definition was based on WHO criteria. Patients were managed according to the guidelines by Scientific Board of Ministry of Health of Turkey. Primary outcomes were length of hospitalization, intensive care unit (ICU) requirement, and intubation. Results: We retrospectively evaluated 1,472 COVID-19 adult patients; 57.1% were men (mean age = 51.9 ± 17.7years). A total of 210 (14.3%) had severe pneumonia, 115 (7.8%) were admitted to ICUs, and 69 (4.7%) were intubated during hospitalization. The median (interquartile range) of duration of hospitalization, including ICU admission, was 7 (5–12) days. Favipiravir (n = 328), lopinavir/ritonavir (n = 55), and oseltamivir (n = 761) were administered as antiviral agents, and hydroxychloroquine (HCQ, n = 1,382) and azithromycin (n = 738) were used for their immunomodulatory activity. Lopinavir/ritonavir (β [95% CI]: 4.71 [2.31–7.11]; p = 0.001), favipiravir (β [95% CI]: 3.55 [2.56–4.55]; p = 0.001) and HCQ (β [95% CI]: 0.84 [0.02–1.67]; p = 0.046) were associated with increased risk of lengthy hospital stays. Furthermore, favipiravir was associated with increased risks of ICU admission (OR [95% CI]: 3.02 [1.70–5.35]; p = 0.001) and invasive mechanical ventilation requirement (OR [95% CI]: 2.94 [1.28–6.75]; p = 0.011). Conclusion: Our findings demonstrated that antiviral drugs including lopinavir, ritonavir, and favipiravir were associated with negative clinical outcomes such as increased risks for lengthy hospital stay, ICU admission, and invasive mechanical ventilation requirement. Therefore, repurposing such agents without proven clinical evidence might not be the best approach for COVID-19 treatment. Copyright © 2022 Babayigit, Kokturk, Kul, Cetinkaya, Atis Nayci, Argun Baris, Karcioglu, Aysert, Irmak, Akbas Yuksel, Sekibag, Baydar Toprak, Azak, Mulamahmutoglu, Cuhadaroglu, Demirel, Kerget, Baran Ketencioglu, Ozger, Ozkan, Ture, Ergan, Avkan Oguz, Kilinc, Ercelik, Ulukavak Ciftci, Alici, Nurlu Temel, Ataoglu, Aydin, Cetiner Bahcetepe, Gullu, Fakili, Deveci, Kose, Tor, Gunluoglu, Altin, Turgut, Tuna, Ozturk, Dikensoy, Yildiz Gulhan, Basyigit, Boyaci, Oguzulgen, Borekci, Gemicioglu, Bayraktar, Elbek, Hanta, Kuzu Okur, Sagcan, Uzun, Akgun, Altinisik, Dursun, Cakir Edis, Gulhan, Oner Eyuboglu, Gultekin, Havlucu, Ozkan, Sakar Coskun, Sayiner, Kalyoncu, Itil and Bayram.
  • No Thumbnail Available
    Item
    Picturing asthma in Turkey: results from the Turkish adult asthma registry
    (Taylor and Francis Ltd., 2023) Celik G.E.; Aydin O.; Gokmen D.; Koycu Buhari G.; Celebi Sozener Z.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Koca Kalkan I.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Oner Erkekol F.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Yilmazel Ucar E.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Turk M.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Polat Yulug D.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Tas Gulen S.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Arslan B.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Pasaoglu Karakis G.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Omeroglu Simsek G.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.
    Introduction: National data on asthma characteristics and the factors associated with uncontrolled asthma seem to be necessary for every country. For this purpose, we developed the Turkish Adult Asthma Registry for patients with asthma aiming to take a snapshot of our patients, thereby assigning the unmet needs and niche areas of intervention. Methods: Case entries were performed between March 2018 and March 2022. A web-based application was used to record data. Study outcomes were demographic features, disease characteristics, asthma control levels, and phenotypes. Results: The registry included 2053 patients from 36 study centers in Turkey. Female subjects dominated the group (n = 1535, 74.8%). The majority of the patients had allergic (n = 1158, 65.3%) and eosinophilic (n = 1174, 57.2%) asthma. Six hundred nineteen (32.2%) of the patients had obese asthma. Severe asthma existed in 670 (32.6%) patients. Majority of cases were on step 3–5 treatment (n: 1525; 88.1%). Uncontrolled asthma was associated with low educational level, severe asthma attacks in the last year, low FEV1, existence of chronic rhinosinusitis and living in particular regions. Conclusion: The picture of this registry showed a dominancy of middle-aged obese women with moderate-to-severe asthma. We also determined particular strategic targets such as low educational level, severe asthma attacks, low FEV1, and chronic rhinosinusitis to decrease uncontrolled asthma in our country. Moreover, some regional strategies may also be needed as uncontrolled asthma is higher in certain regions. We believe that these data will guide authorities to reestablish national asthma programs to improve asthma service delivery. © 2023 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Socioeconomic status has direct impact on asthma control: Turkish adult asthma registry
    (John Wiley and Sons Inc, 2025) Arslan B.; Türk M.; Hayme S.; Aydin Ö.; Gokmen D.; Buhari G.K.; Sozener Z.C.; Gemicioglu B.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Oguzulgen I.K.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Cetin G.P.; Soyyigit S.; Kara B.Y.; Karakis G.P.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Sevinc C.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Celik G.E.; Uysal M.A.
    Background: Asthma is one of the most common causes of chronic respiratory disease, and countries with low socioeconomic status have both a high prevalence of asthma and asthma-related death. Objective: In this study, we aimed to determine socioeconomic levels of asthmatic patients according to a national database and investigate the effects of social markers on disease control in our region. Methods: This is an analysis of data from 2053 adult asthma patients from a multicentre chart study in Turkey. Socioeconomic status (SES) data were collected from questionnaires and this form was sent to the patients via e-mail. Parameters related to social status and poor disease control were analyzed. Results: Illiteracy (OR:2.687 [95% CI: 1.235–5.848]; p = 0.013) and lower household income (OR:1,76 [95% CI: 1.002–3.09]; p = 0.049) were found as independent risk factors for hospitalization in the multivariate logistic regression analysis. Therewithal, being aged between 40 and 60 (OR: 1.435 [95% CI: 1.074–1.917]; p = 0.015), illiteracy (OR: 2.188 [95% CI: 1.262–3.795]; p = 0.005) and being employed (OR: 1.466 [95% CI: 1.085–1.847]; p = 0.011) were considered as independent risk factors for systemic corticosteroid use at least 3 days within last 1 year. Conclusion: As a result of our national database, education level, household income and working status briefly socioeconomic status have impacts on asthma control. Identification of social markers in asthma and better recognition of risk factors based on the population gives us clues to provide better asthma control in the future. © 2025 The Author(s). Clinical and Translational Allergy published by John Wiley & Sons Ltd on behalf of European Academy of Allergy and Clinical Immunology.
  • No Thumbnail Available
    Item
    Asthma patients with obesity have a unique phenotype: a subanalysis of the Turkish adult asthma registry
    (Taylor and Francis Ltd., 2025) Celebi Sozener Z.; Oguzulgen I.K.; Ozalp Ates F.S.; Baccioglu A.; Argun Barıs S.; Ediger D.; Gunaydın F.E.; Sevinc C.; Seker U.; Yılmaz Kara B.; Beyaz S.; Mungan D.; Aydin O.; Gokmen D.; Buhari G.K.; Gemicioglu B.; Bulut I.; Orcen C.; Kepil Ozdemir S.; Keren M.; Damadoglu E.; Yakut T.; Kalpaklioglu A.F.; Alan Yalim S.; Yilmaz I.; Koca Kalkan I.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Akkor Gelincik A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Oner Erkekol F.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Basyigit I.; Yilmazel Ucar E.; Erdogan T.; Polatli M.; Turk M.; Pur L.; Yegin Katran Z.; Sekibag Y.; Aykac E.F.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Can A.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Polat Yulug D.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Havlucu Y.; Donmez H.; Arslan B.; Cetin G.P.; Soyyigit S.; Pasaoglu Karakis G.; Dursun A.B.; Kendirlinan R.; Ozturk A.B.; Omeroglu Simsek G.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Cadalli Tatar E.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Celik G.E.
    Objective: The obese-asthma phenotype has gradually increased in the last few years. We aimed to assess the differences between obese and non-obese patients with asthma. Methods: This research is a subanalysis of the Turkish Adult Asthma Registry (TAAR). Clinical presentation, disease control, severity, and demographics of obese and non-obese (normal-weight, overweight) patients were compared. Results: The obesity rate in TAAR was 32.2% (n = 619/1919; 18-83 years; 527 F/92 M). Patients with asthma and obesity had higher rates of childhood obesity, longer symptom duration, later onset of asthma, and more severe asthma. These patients were more likely to be female, older, less educated, and live in rural areas. Patients with obesity had more scheduled visits and emergency visits compared with non-obese patients, but similar asthma control, oral corticosteroid use, hospitalizations, intensive care unit admissions, and unscheduled visits. They also had a higher frequency of T2-high but lower frequency of possible T2-low phenotypes compared with normal-weight asthmatics. The risk of severe asthma in patients with obesity was 6.04 times higher for allergic than non-allergic patients and 3.58 times higher for the T2-high phenotype than for possible T2-low phenotypes. A one-unit increase in the asthma control test reduced the risk of severe asthma by 22%. Conclusions: A good definition of this phenotype is important to ensure that appropriate treatment strategies are implemented to achieve the control goal. We also believe that prevention of childhood obesity is an effective and pivotal strategy to achieve the goal of asthma control. © 2025 Taylor & Francis Group, LLC.
  • No Thumbnail Available
    Item
    Factors influencing the prescription of add-on long-acting muscarinic antagonists in real-world asthma management: Insights from a national registry
    (W.B. Saunders Ltd, 2025) Gemicioglu B.; Gokmen D.; Can A.; Sevinc C.; Oguzulgen I.K.; Soyyigit S.; Yakut T.; Havlucu Y.; Aydin O.; Buhari G.K.; Sozener Z.C.; Bulut I.; Beyaz S.; Orcen C.; Ozdemir S.K.; Keren M.; Damadoglu E.; Kalpaklioglu A.F.; Baccioglu A.; Yalim S.A.; Yilmaz I.; Kalkan I.K.; Uysal M.A.; Ozgun Niksarlioglu E.Y.; Kalyoncu A.F.; Karakaya G.; Erbay M.; Nayci S.; Tepetam F.M.; Gelincik A.; Dirol H.; Goksel O.; Karaoglanoglu S.; Erkekol F.O.; Isik S.R.; Yildiz F.; Yavuz Y.; Karadogan D.; Bozkurt N.; Seker U.; Basyigit I.; Baris S.A.; Ucar E.Y.; Erdogan T.; Polatli M.; Ediger D.; Gunaydin F.E.; Turk M.; Pur L.; Katran Z.Y.; Sekibag Y.; Aykac E.F.; Mungan D.; Gul O.; Cengiz A.; Akkurt B.; Ozden S.; Demir S.; Unal D.; Aslan A.F.; Gumusburun R.; Bogatekin G.; Akten H.S.; Inan S.; Erdinc M.; Ogus A.C.; Kavas M.; Yulug D.P.; Cakmak M.E.; Kaya S.B.; Alpagat G.; Ozgur E.S.; Uzun O.; Gulen S.T.; Pekbak G.; Kizilirmak D.; Donmez H.; Arslan B.; Cetin G.P.; Kara B.Y.; Dursun A.B.; Karakis G.P.; Kendirlinan R.; Ozturk A.B.; Simsek G.O.; Abadoglu O.; Cerci P.; Yucel T.; Yorulmaz I.; Tezcaner Z.C.; Tatar E.C.; Suslu A.E.; Ozer S.; Dursun E.; Yorgancioglu A.; Çelik G.E.
    Current guidelines recommend adding long-acting muscarinic antagonists (LAMAs) in patients with uncontrolled asthma, despite the use of moderate to high doses of inhaled steroid-long-acting beta agonists (ICS/LABA). This study aims to analyze the factors related to the prescription of add-on LAMA in clinical practice for asthma patients, shedding light on physicians’ preferences. This study included adult asthma patients on add-on LAMA and ICS/LABA monitored for at least one year in a national registry comprising 2053 asthmatics. Patients’ characteristics and disease profiles were analyzed to identify factors associated with the prescription of add-on LAMA across the entire cohort. A comparative analysis was performed among three groups: MART (ICS/formoterol as a maintenance and reliever therapy) plus LAMA, Conventional (ICS/LABA as a maintenance and short-acting beta agonist as reliever) plus LAMA and Triple (ICS/LABA/LAMA single inhaler). LAMAs were added to ICS/LABA in 11.7 % of patients in the national registry. Logistic regression analysis revealed that older age, low FEV1 (%), Asthma Control Test (ACT) scores less than 20, and severe exacerbation were the main factors influencing the initiation of LAMA in our registry. However, demographic characteristics of asthma, control status, pulmonary function test results were similar among the three groups of LAMA users (p > 0.05). Physicians used LAMAs without phenotyping based on allergic status or eosinophil levels (p > 0.05). Mepolizumab was added after LAMA in all patients, while omalizumab was initiated before LAMA in 16.9 % of the patients receiving LAMA along with biologics. Add-on LAMAs were predominantly prescribed for older, uncontrolled, and exacerbated asthma patients with low FEV1. © 2024 Elsevier Ltd